US FDA approves Lupin's Meloxicam Capsules
3 June 2020 -

India based pharmaceutical company, Lupin Limited, announced on Tuesday that it has received approval for its Meloxicam Capsules, 5mg and 10mg, from the United States Food and Drug Administration (US FDA), to market as a generic equivalent of Vivlodex(R) Capsules, 5mg and 1 mg, from Zyla Life Sciences US Inc.

The product will be manufactured at Lupin's Aurangabad facility, India, and is expected to be launched shortly. Meloxicam Capsules, 5mg and 10mg, are indicated for management of osteoarthritis (OA) pain.

Meloxicam Capsules (RLD: Vivlodex(R)) had annual sales of approximately USD14m in the US (IQVIA MAT March 2020).